These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24634681)

  • 1. Respiratory syncytial virus and palivizumab: Where are we in 2014?
    Robinson J
    Can J Infect Dis Med Microbiol; 2014; 25(1):11-2. PubMed ID: 24634681
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children.
    Viguria N; Navascués A; Juanbeltz R; Echeverría A; Ezpeleta C; Castilla J
    Hum Vaccin Immunother; 2021 Jun; 17(6):1867-1872. PubMed ID: 33502928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017.
    Kim D; Saleem M; Paes B; Mitchell I; Lanctôt KL
    Clin Infect Dis; 2019 Aug; 69(6):980-986. PubMed ID: 30517603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a Novel Palivizumab Prophylaxis Protocol for Respiratory Syncytial Virus Infection in Congenital Heart Disease: A Multicenter Study.
    Chiu SN; Wang JN; Fu YC; Chung HT; Chang LY; Wu MH; Hua YC; Lin MT; Lu CW; Chen CA; Wu JM; Wang JK
    J Pediatr; 2018 Apr; 195():108-114.e1. PubMed ID: 29395174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA; Odelola OA; Saldanha IJ
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD007743. PubMed ID: 27439110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA; Odelola OA; Saldanha IJ
    Cochrane Database Syst Rev; 2014 May; (5):CD007743. PubMed ID: 24851825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA; Odelola OA; Saldanha IJ; McKoy NA
    Cochrane Database Syst Rev; 2013 Jun; (6):CD007743. PubMed ID: 23737087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA; Odelola OA; Saldanha IJ; McKoy NA
    Cochrane Database Syst Rev; 2012 Feb; (2):CD007743. PubMed ID: 22336832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis.
    Checchia PA; Nalysnyk L; Fernandes AW; Mahadevia PJ; Xu Y; Fahrbach K; Welliver RC
    Pediatr Crit Care Med; 2011 Sep; 12(5):580-8. PubMed ID: 21200358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of palivizumab in preterm infants 29 to 32 weeks' gestational age without chronic lung disease to prevent serious respiratory syncytial virus infection.
    Groothuis JR
    Eur J Clin Microbiol Infect Dis; 2003 Jul; 22(7):414-7. PubMed ID: 12827537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    Meissner HC; Long SS;
    Pediatrics; 2003 Dec; 112(6 Pt 1):1447-52. PubMed ID: 14654628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
    Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
    Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization.
    Raghunandan R; Lu H; Zhou B; Xabier MG; Massare MJ; Flyer DC; Fries LF; Smith GE; Glenn GM
    Vaccine; 2014 Nov; 32(48):6485-92. PubMed ID: 25269094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab.
    Chida-Nagai A; Sato H; Sato I; Shiraishi M; Sasaki D; Izumi G; Yamazawa H; Cho K; Manabe A; Takeda A
    Eur J Pediatr; 2022 Feb; 181(2):539-547. PubMed ID: 34417646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Respiratory-syncytial virus immunoprophylaxis on asthma symptoms development in prematurity with bronchopulmonary dysplasia.
    Fang LC; Wang JY; Yu HH; Wang LC; Chiang BL
    J Allergy Clin Immunol Glob; 2023 Nov; 2(4):100161. PubMed ID: 37781666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia.
    Piñeros JG; De la Hoz-Valle J; Galvis C; Celis A; Ovalle O; Sandoval CC; Orrego J; Vides S; Rojas I; Bustamante H; Gallón C; Mesa JA
    J Infect Dev Ctries; 2021 Nov; 15(11):1708-1713. PubMed ID: 34898500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.
    Broadbent L; Parke HG; Ferguson LJ; Millar A; Shields MD; Detalle L; Power UF
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab.
    Wang DY; Saleem M; Paes BA; Mitchell I; Li A; Lanctôt KL;
    Pediatr Infect Dis J; 2019 Aug; 38(8):775-780. PubMed ID: 30985509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory infections in children up to two years of age on prophylaxis with palivizumab.
    Monteiro AI; Bellei NC; Sousa AR; dos Santos AM; Weckx LY
    Rev Paul Pediatr; 2014 Jun; 32(2):152-8. PubMed ID: 25119744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.